[PET/CT in Lymphoma Patients]

Overview

Journal Radiologe

Specialty Radiology

Date 2004 Nov 2

PMID 15517141

Citations 3

Authors

H C Steinert

Affiliations

Soon will be listed here.

Abstract

Purpose: First results of PET/CT in Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) are reported.

Patients And Methods: From March 2001 to August 2004 822 PET/CT were performed at our clinic in lymphoma patients for primary staging, restaging after therapy, and diagnosis of recurrence. For coregistration non contrast-enhanced low-dose CT were used.

Results: Due to the exact anatomic localization of (18)F-FDG accumulating lesions equivocal or false positive PET findings are avoided. In comparison to contrast enhanced CT, PET/CT has a higher sensitivity and specificity in patients with HD and aggressive NHL. Integration of PET/CT in treatment planning of radiation therapy optimizes the field volume.

Conclusion: Even in the initial phase of clinical evaluation, PET/CT has proven useful in staging and restaging of lymphoma. The exact anatomic localization of the PET findings is essential for a precise report, for treatment planning of radiation therapy, and for planning surgical biopsy.

Citing Articles

Malaria masquerading as relapse of Hodgkin's lymphoma on contrast enhanced (18)F-fluorodeoxyglucose positron emission tomography/computed tomography: A diagnostic dilemma.

Jeph S, Thakur K, Shamim S, Aggarwal A Indian J Nucl Med. 2014; 29(2):102-4.

PMID: 24761064 PMC: 3996762. DOI: 10.4103/0972-3919.130299.

Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

Fougere C, Hundt W, Brockel N, Pfluger T, Haug A, Scher B Eur J Nucl Med Mol Imaging. 2006; 33(12):1417-25.

PMID: 16858568 DOI: 10.1007/s00259-006-0171-x.

Is PET/CT necessary in paediatric oncology? Against.

Hahn K, Pfluger T Eur J Nucl Med Mol Imaging. 2006; 33(8):966-8.

PMID: 16838141 DOI: 10.1007/s00259-006-0115-5.

References

Schaefer N, Hany T, Taverna C, Seifert B, Stumpe K, von Schulthess G . Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?. Radiology. 2004; 232(3):823-9. DOI: 10.1148/radiol.2323030985. View

Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske S, Bergmann L . Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 1999; 38(6):799-804. DOI: 10.1080/028418699432969. View

Cook G, Fogelman I, Maisey M . Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996; 26(4):308-14. DOI: 10.1016/s0001-2998(96)80006-7. View

Hany T, Gharehpapagh E, Kamel E, Buck A, Himms-Hagen J, von Schulthess G . Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002; 29(10):1393-8. DOI: 10.1007/s00259-002-0902-6. View

Dizendorf E, Baumert B, von Schulthess G, Lutolf U, Steinert H . Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med. 2003; 44(1):24-9. View

Tatsumi M, Cohade C, Nakamoto Y, Wahl R . Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology. 2003; 229(3):831-7. DOI: 10.1148/radiol.2293021168. View

Schoder H, Larson S, Yeung H . PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004; 45 Suppl 1:72S-81S. View

Glatz S, Kotzerke J, Moog F, Sandherr M, Heimpel H, Reske S . [Simulation of a mediastinal non-Hodgkin lymphoma recurrence by a diffuse thymus hyperplasia in 18F-FDG PET scan]. Rofo. 1996; 165(3):309-10. DOI: 10.1055/s-2007-1015764. View

Fayad L, Cohade C, Wahl R, Fishman E . Sacral fractures: a potential pitfall of FDG positron emission tomography. AJR Am J Roentgenol. 2003; 181(5):1239-43. DOI: 10.2214/ajr.181.5.1811239. View

10.

Alavi A, Gupta N, Alberini J, Hickeson M, Adam L, Bhargava P . Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2003; 32(4):293-321. DOI: 10.1053/snuc.2002.127291. View

11.

Hueltenschmidt B, Sautter-Bihl M, Lang O, Maul F, Fischer J, Mergenthaler H . Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001; 91(2):302-10. View

12.

Tatlidil R, Jadvar H, Bading J, Conti P . Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002; 224(3):783-7. DOI: 10.1148/radiol.2243011214. View

13.

Gambhir S, Czernin J, SCHWIMMER J, Silverman D, Coleman R, Phelps M . A tabulated summary of the FDG PET literature. J Nucl Med. 2001; 42(5 Suppl):1S-93S. View

14.

Jacobsson H, Celsing F, Ingvar M, Stone-Elander S, Larsson S . Accumulation of FDG in axillary sweat glands in hyperhidrosis: a pitfall in whole-body PET examination. Eur Radiol. 1998; 8(3):482-3. DOI: 10.1007/s003300050421. View

15.

Kamel E, Goerres G, Burger C, von Schulthess G, Steinert H . Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion -- report of six cases. Radiology. 2002; 224(1):153-6. DOI: 10.1148/radiol.2241011254. View

16.

Ciernik I, Dizendorf E, Baumert B, Reiner B, Burger C, Bernard Davis J . Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003; 57(3):853-63. DOI: 10.1016/s0360-3016(03)00346-8. View

17.

Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser E, Nitzsche E . Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?. Radiology. 1998; 209(1):253-8. DOI: 10.1148/radiology.209.1.9769840. View

18.

Schiepers C, Filmont J, Czernin J . PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003; 30 Suppl 1:S82-8. DOI: 10.1007/s00259-003-1165-6. View

19.

Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A . Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003; 44(8):1200-9. View

20.

Chander S, Meltzer C, McCook B . Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med. 2002; 27(1):22-4. DOI: 10.1097/00003072-200201000-00005. View